Good afternoon, thank you for standing by. Welcome to Soleno Therapeutics' fourth quarter and full-year 2025 financial and operating results conference call and webcast. Currently, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ritchie of LifeSci Advisors. Please go ahead. Thank you. Good afternoon, everyone, and thank you for joining us to discuss Soleno Therapeutics' fourth quarter and full-year 2025 financial and operating results. Please note, we'll be making certain forward-looking statements today. We refer you to Soleno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today for Soleno are Anish Bhatnagar, Soleno's Chairman and Chief Executive Officer; Meredith Manning, Soleno's Chief Commercial Officer; and Jim Mackaness, Soleno's Chief Financial Officer. With that, I will now turn the call over to Anish. Thank you, Brian, thank you everyone for joining us for our fourth quarter and year-end results call this afternoon. As has been our practice, following my brief opening remarks, Meredith will review the company's commercialization progress to date, and Jim will cover the company's financial statements for the fourth quarter and for the year. I will spend a few minutes outlining our thoughts and plans on expanding beyond Prader-Willi syndrome, after which we will open the call for questions. We finished 2025 on a very strong note, driven by a continuation of many of the positive trends that we have seen since VYKAT XR was commercially launched in the second quarter of last year. Consistent with our pre-announcement press release from January 12th, total net revenue for the fourth quarter was $91.7 million, which brings our total net revenue for the full-year, which was less than nine months of sales, to $190.4 million. We achieved profitability with positive net income for the year of $20.9 million, became cash flow positive, including generating $48.7 million of cash from operating activities in the fourth quarter, and ended the year with over $500 million of cash equivalents, and marketable securities. All of these are outstanding results. This has been an incredibly successful launch, made possible by the entire team at Soleno, who come to work each day to help fulfill our mission of improving the lives of people with serious rare diseases. We are very pleased to see such durable and exciting growth nine months post-launch. Looking ahead, our leading indicators are strong. Since launch through December 31st, 2025, we received 1,250 patient start forms, which represents approximately 12.5% of the U.S. VYKAT XR addressable market, and as of December 31st, there were 859 people on active treatment. We believe we can sustain our current momentum and capture an additional approximately 1,000 start forms over the next nine to 12 months. This bodes well not only for the thousands of people with PWS and their caregivers, who struggle with the significant daily burden of hyperphagia, but also for our company, which is poised to generate significant long-term value. Importantly, the real-world safety profile of VYKAT XR continues to mirror our expectations and the clinical long-term safety profile of the product. This is significant when you reflect on the complexity of PWS and all the serious comorbidities of this very vulnerable and fragile patient population. The cumulative launch-to-date discontinuation rate of VYKAT XR related to adverse events was approximately 12% as of the end of the fourth quarter, and the total discontinuation rate was about 15%. As stated earlier, we expect a long-term discontinuation rate of 15%-20%. We're now seeing more and more success stories emerge as individuals with PWS related to hyperphagia have been on therapy for multiple months, and we are seeing interest spread across all stakeholders, particularly among caregivers, who endure a very significant burden in caring for someone with PWS who exhibits hyperphagia. We believe this dynamic will build as we progress through 2026. I would now like to provide a brief update on our activities in support of potential approval of DCCR in the EU. Last May, we announced the submission and EMA validation of our marketing authorisation application. We subsequently received Day 120 questions. All responses were submitted before the end of the year. As we've indicated before, the nature of the key questions centered around the adequacy of the data to prove efficacy, based primarily on our randomized control study. The next step is for us to receive Day 180 questions from the EMA around the end of February. We continue to anticipate a decision in the mid-year 2026 timeframe. We are considering a range of commercialization options in the EU and have continued to develop our own team and capabilities on the ground. It is a significant market opportunity. We have said previously that we believe that there are about 9,500 people living with PWS in the U.K. and the EU4. Further, perhaps more so than in the U.S., it is a concentrated market driven by centers of excellence, and there is strong thought leader support for VYKAT XR. We look forward to keeping you apprised of our progress over the next few months as we approach a regulatory decision and potential commercial launch. Now, I'd like to turn the call over to Meredith for a detailed commercial update. Meredith? Thank you, Anish. Good afternoon, everyone. As Anish mentioned, 2025 was an important year for the PWS community and Soleno. ... as we brought to market the first FDA-approved medicine for the treatment of hyperphagia in adults and children four years of age and older, living with Prader-Willi syndrome. We are encouraged that 1,250 new patient start forms were submitted for VYKAT XR from launch on March 26th through year-end, which included 207 in the fourth quarter. This represents approximately 12.5% of the total U.S. VYKAT XR addressable market. At the end of the fourth quarter, 859 individuals were being actively treated with VYKAT XR, up from 764 at the end of Q3, indicating that VYKAT XR is being adopted into clinical practice and reflecting our ability to convert start forms into treated patients. On the prescriber side, our efforts to raise awareness of VYKAT XR's availability and clinical profile have driven strong engagement. In Q4, we added 136 new prescribers, bringing the total unique prescribers to 630 as of December 31st. We continue to hear that VYKAT XR delivers meaningful clinical benefits, physicians plan to proactively discuss the first to market therapy with caregivers and patients as they consider treatment options. Our field teams are not only educating but also activating the prescriber base by providing comprehensive support on therapeutic expectations, monitoring, and dose modification where necessary. These are critical elements that give physicians the confidence to initiate and maintain patients on VYKAT XR and to integrate our medicine into routine clinical practice. A few things stand out when we look at who is being treated and who is prescribing. While most patients are between four and 26 years of age, we are also seeing meaningful utilization in adults, particularly those 27 to 45 years old. This speaks to VYKAT's relevance across the PWS population. Side effects reported in the real-world setting have been consistent with those observed in our clinical trials and with the FDA-approved label. As patients settle into their optimal target dose, adherence has remained high, with a launch-to-date discontinuation rate related to adverse events of approximately 12% at the end of the quarter. We are also leaning into real-world experience to support demand. We are systematically capturing success stories with VYKAT XR to highlight its impact on hyperphagia and to support more proactive treatment discussions. Through community outreach, including patient webinars and live events where families hear directly from others treated with VYKAT XR, we are sustaining strong interest and supporting ongoing launch momentum. Our January patient webinar attracted over 200 registrants, nearly 60 more than our November event, underscoring growing interest in VYKAT XR. We are also collecting feedback from families who have attended these programs, and while still early, we have already heard of families who, after attending these events, have proactively asked their physicians about VYKAT XR, encouraging signals that our education efforts are helping to drive appropriate demand and convert interest into active treatment. Looking ahead to 2026, our priority is to deepen experience and adoption across leading academic and endocrine centers, specifically among PWS experts who shape practice patterns, while further broadening the prescriber base in the community, where many people with PWS are treated. We are seeing growing confidence among these key experts in utilizing VYKAT XR, and we have made important strides in creating champions among both HCPs and PWS families, which we believe will continue to support wider uptake over time and advance our goal of making VYKAT XR the standard of care for appropriate patients with PWS-related hyperphagia. We continue to secure broad coverage for VYKAT XR across all channels, commercial, Medicaid, and Medicare, resulting in policies that covered over 180 million lives at the end of the fourth quarter. Additionally, we have strong coverage or reimbursed claims from approximately 45 state Medicaid programs through Q4. Payers continue to recognize the seriousness of PWS, understand the true unmet need in treating hyperphagia, and appreciate the meaningful value VYKAT XR can deliver. We are seeing this clearly play out in the reauthorization process. As a reminder, payers typically require reauthorization every six to 12 months for rare disease medicines. We are pleased to see the overwhelming majority of claims for patients have been quickly processed and continued on paid products. In summary, we believe 2025 has established a solid foundation with patients, prescribers, and payers for VYKAT XR. Looking ahead, we are committed to deepening adoption and expanding our prescriber base in both the KOL and community settings, while keeping families and individuals with PWS experiencing hyperphagia at the forefront as we realize the full potential of the first approved treatment for this condition. I will now turn the call over to Jim for a review of the company's financial statement for the fourth quarter. Thank you, Meredith. Total net revenue for the fourth quarter ended December 31, 2025, was $91.7 million, representing sequential growth of nearly 40% from $66 million in Q3. For the full-year 2025, which as a reminder, represents less than nine months of commercial availability, total net revenue was $190.4 million. VYKAT XR was approved in March of this year, and therefore the company generated no revenue for the three or 12 months ending December 31, 2024. We generated $48.7 million of cash from operating activities for the fourth quarter and achieved profitability with positive net income of $20.9 million for the full-year 2025. At the end of the year, we had $506.1 million of cash equivalents, and marketable securities. Please note, this is after our investment of $100 million in the accelerated share repurchase program that we announced in November. Our strong balance sheet ensures that we are sufficiently capitalized to continue to execute an effective U.S. launch of VYKAT XR, while in parallel progressing towards regulatory approvals and commercialization, either on a standalone basis or with partners in the EU and other geographies, and to begin investments in possible new indications. Cost of goods sold was $0.9 million for the fourth quarter and $2.7 million for the full-year. As a reminder, prior to FDA approval, costs associated with manufacturing VYKAT XR were expensed as research and development expenses. As such, a portion of the cost of goods sold during these periods included inventory at $0 cost. Going forward, as we continue to sell VYKAT XR, we will deplete our zero-cost inventory and replenish it with at-cost inventory. Consequently, cost of goods sold as a percent of revenue will increase. Research and development expense for the fourth quarter was $9.6 million, which included $2.8 million of non-cash stock-based compensation, compared to $21.5 million, which includes $10.1 million of non-stock, non-cash stock-based compensation for the same period of 2024. The cadence of our research and development expenditures fluctuates depending upon the state of our research activities, clinical programs, the timing of manufacturing and other projects necessary to support submission of regulatory filings. For the full-year 2025, research and development expenses were $40.6 million, as compared to $78.6 million for the full-year 2024. Selling, general, and administrative expense for the fourth quarter ended December 31, 2025, was $40.9 million, which includes $8.7 million of non-cash stock-based compensation, compared to $37.3 million, which includes $19.7 million of non-cash stock-based compensation for the same period of 2024. The increase in expense, after removing stock-based compensation, reflects our ongoing investment in additional personnel and new programs to support the VYKAT XR commercial launch and in support of our increased business activities. For the full-year 2025, SG&A expense were $132.1 million, as compared to $105.9 million for the full-year 2024. Total other income net was $3.8 million for the three months ending December 31, 2025, compared to total other income net of $3.1 million in the same period of 2024. For the full-year 2025, total other income net was $11.5 million, as compared to $11.8 million for the full-year 2024. Net income for the fourth quarter was approximately $43.4 million, or $0.82 per basic and $0.80 per diluted share, compared to a net loss of $56.0 million, or $1.27 per basic and diluted share for the same period in 2024. For the full-year 2025, net income was $20.9 million, or $0.40 per basic and $0.39 per diluted share, as compared to a net loss of $175.9 million, or $4.38 per basic and diluted share for 2024. Please note, with regards to KPIs, we intend to share patient start forms, number of unique prescribers, and lives covered in our Q1 2026 earnings call, which will mark 12 months of results, and our intention is to retire these metrics at that time. This concludes the financial overview. On a personal note, I would like to let everyone know that I am retiring at the end of March. It's been my great pleasure to work with Anish and the team over the last six years. It's been a fantastic journey. We've accomplished so much, and I feel the company is in an excellent position to ensure future success. We have an outstanding replacement, Jennifer Volk, who will take over as CFO in the coming weeks, and I will move into a consulting role to ensure a smooth transition. Now I'll turn the call back over to Anish for additional thoughts. Anish? Thank you, Jim, for the incredible work over the last six years to get us to where we are today. With the launch of VYKAT XR well underway, we turn our attention to what's next for the company, and to begin with, what's next for DCCR. We continue to pursue additional metabolic rare disease indications with high unmet needs, where the probability of success is high and the mechanism of action directly applies. The first of these indications is Glycogen Storage Disease Type I, or GSD I, which is a rare metabolic condition characterized by the accumulation of fat in the liver and kidneys, resulting in extremely low levels of blood glucose. It impacts approximately one in every 100,000 live births, resulting in a prevalence of greater than 7,000 patients globally and approximately 3,000-4,000 of the patients residing in the U.S. There are currently no FDA-approved therapies. GSD I represents a natural and logical extension of our VYKAT XR franchise beyond PWS. The predominant physician ballpark for GSD I, namely pediatric endocrinologist, is the same for PWS. The mechanism of action of VYKAT XR are uniquely addresses the severe clinical manifestations of GSD I. People affected by GSD I lack the ability to convert stored glycogen into glucose and live at the constant risk of life-threatening hypoglycemia. They are dependent upon external sources of glucose, in this case, daily consumption of cornstarch multiple times a day in order to survive. The precise timing of cornstarch consumption is critical, especially during periods of fasting between meals and during the night, as missed doses can lead to potentially fatal hypoglycemia. Long-term use of cornstarch can lead to severe GI issues, metabolic dysfunction, and very poor quality of life. VYKAT XR's ability to innovate insulin secretion with its fast onset and repeatable and tailored dosing, could maintain proper levels of glucose throughout the day and night and reduce the person's dependency on cornstarch. DCCR has orphan designation for GSD I in the U.S. as well as in the EU. Our plan is to file an IND in the first half of this year and to initiate a clinical program later in 2026. More detail will be provided during the year as we approach the start of the trial. We look forward to sharing future updates on these programs as they emerge. In closing, we are very pleased with the success and trajectory of VYKAT XR, and we will continue to work tirelessly to make this safe and effective therapy available to as many patients living with PWS-related hyperphagia as possible. We're excited about expanding into new indications, leveraging our existing knowledge and skills. With that, we'll now open the call for your questions. Operator? Ladies and gentlemen, we will now begin the question and answer session. If you have a question, please press star followed by the number one on your touchtone phone. You will hear a prompt that your hand has been raised. If you would like to withdraw from the polling process, please press star, then the number two. If you are using a speakerphone, please make sure to lift your handset before pressing any keys. Your first question comes from the line of Paul Choi from Goldman Sachs. Please go ahead. Hi, Jim and Anish. This is Khalil calling in for Paul. Thank you so much for taking the question, and congrats on the quarter. I supposedly just wanted to start quick one with us for on the 1,000 patient start forms that you got for the next nine to 12 months. Can you remind us what the cadence of that is expected to look like? Is there going to be a bolus in the start of the year? Is that going to be later in the year due to the adjustment, seasonal adjustment in 1 Q? Just to help to understand the cadence there. Thanks for the question, Khalil. I think it's fair to say that we want you to think of this as over the nine to 12 months, not necessarily on a quarter-to-quarter basis. It's hard to, you know, think of a bolus at this time. I think it's fair to say that the start forms will come in over the year. I'll let Meredith address it further in terms of how she thinks the cadence is likely to be. Yeah. Thank you, Anish. I agree with Anish that, obviously we're looking at 1,000 over the next nine to 12 months. That's our goal in order to continue to sustain momentum of the very strong launch. As I mentioned in the script, you know, we're really doubling down on broadening our experience with KOLs, getting out into the community setting, and also activating the caregiver population. Got it. Thank you so much. Jim, congrats on your retirement. We're sorry to see you go. Thank you very much. Appreciate it, Khalil. Your next question comes from the line of Moritz Reiterer from Guggenheim Securities. Please go ahead. Hi, this is Moritz on for Debjit. I got first a question on PWS. At peak, what percent of the market do you think could be accessible in the U.S. at this point? A second one about GSD I. What do you think about dosing in GSD I? Do you think the dose will be similar or lower? How do you think tolerability of the drug would impact adoption in that disease? Thank you. Sure. Your first question was about what is the likely peak penetration in PWS? It's a good question, I think you have to put it in the context of the fact that no other treatments exist today. You know, many of these treatments, you look at 40%, 50% penetration in these larger rare diseases. I think if we are, you know, three, four years out and the competitive landscape looks like the way it does today, I don't think it's unreasonable to expect a higher penetration than that. In terms of GSD, your question around dosing. Part of our first trial is going to be looking at dosing in these patients. We do know that it's a pretty sensitive... Insulin is pretty sensitive to diazoxide, so we expect the dosing to be likely in the range of where we are today. It is important to know, though, that even though the unmet need is really great here, it's really about the precise dosing to increase blood glucose levels enough. These patients don't have the sort of comorbidities that you see in PWS patients, so they're unlikely to be significantly obese, they're unlikely to be significantly diabetic, et cetera. I think there will be more room to do to dose in that patient population, but that remains to be seen, be the subject of the first trial. Your next question comes from the line of Yasmeen Rahimi from Piper Sandler. Please go ahead. Hi, this is Shannon on for Yas. Congrats on the progress, guys, and thank you so much for taking our question. Just two from us. Could you help us understand a little bit more about the refill rates that you're seeing now that you have a larger proportion of patients who have been on the drug for several months? The second question is, how do you expect the average weight of new patients coming in to change over time? If you're seeing more older patients, do you expect the average weight to increase? Thank you. Sure. Shannon, I'll take the second question, Meredith will take the first one. In terms of the weight over time, as you know, our clinical trial average weight was 61 kg. The age was about 13 years. What we have said more recently is that, the predominant number of patients coming in are in the four to 26 year age group, and in general, likely heavier than what we are seeing in the clinical trial population. The average WAC for a clinical trial patient would be about $488. We have said publicly that we're looking at averages in the higher than $500 range. We are also seeing more older patients coming on at this time, and we expect that over time, therefore, the total weight will be going up as well. Again, these are not likely to be large stepwise inflections, but think of it more as sort of gentle increases over time. Meredith, you want to talk about refill rates, realizing that it's early and we don't really. Yeah. have that much data? Yeah. Thank you. Similar to what I said in my prepared remarks, if you, look at, as the patients are settling into their optimal dose, we're very pleased with the high, adherence rates and seeing that we are, you know, nine months in, at the end of Q4, we're seeing patients who are able to, stay on therapy and reach, longer time frames. We're very pleased with the refill rates. Great. Thank you so much. Your next question comes from the line of Kristen Kluska from Cantor. Please go ahead. Hi, thanks for taking the questions, and congrats, Jim. It's been an absolute pleasure working with you and always wishing you the best. You talked about longer term, maybe factoring in a 15%-20% discontinuation rate. I'm wondering how you're thinking, how efficacy will ultimately play into this. At what point in the launch do you think you'll have a good sense of percent of patients that are dropping out due to lack of efficacy? Then I'm curious, as you are collecting some of these real-world anecdotes, if the efficacy looks similar or different amongst patients, meaning, are there some that are responding to hyperphagia? Are there some that are responding on behavior? What's really the factor that will keep somebody on the therapy longer term from efficacy standpoint? Thanks, Kristen. I think it's fair to say that when you look at our experience in the clinical trials, which, as you know, lasted for many years, if you stay on therapy, you are likely to see benefits. As you can imagine, you're unlikely to stay on therapy if you have significant adverse events. What we have seen to date is that patients who have stayed on drug for some time are seeing efficacy. I think it's fair to say that discontinuations for lack of efficacy are few at this time, and I would not expect that to change too much, because if you stay on drug, we expect you to have some levels of efficacy. Okay. Just on what that efficacy actually is in the real world, is it looking different in patients? Meaning, are some responding to hyperphagia or are some responding to behavior? Is it like a mix? Yeah, it's a good question. As you know, we don't have the same precise gauge on efficacy in the real world as we do in the clinical trials. We're not, you know, doing efficacy analyses per se. The anecdotes that we're hearing certainly primarily relate to changes in hyperphagia and the downstream effects of it. As you know, hyperphagia itself gets mixed up with, you know, anxiety related to food, behaviors, aggressive behaviors around food. As long as you're targeting something around hyperphagia, we think that is the primary effect. I think the other effects will. Time will tell. It's hard for us to measure those, even in the trials. We do hear anecdotes, you know, that talk about, you know, being more calm, having better social interactions, having less anxiety, and things like that. Yes, there is an element of that as well. Thank you. Your next question comes from the line of Tyler Van Buren from TD Cowen. Please go ahead. Great. Thanks, guys. I'll add my congratulations to you, Jim, on your retirement and the success you've experienced at Soleno. You'll be missed. Wanted to just follow up on the 1,000 start forms over the next nine to 12 months that you guys reiterated, which is, of course, encouraging. Earlier you spoke about the cadence, in response to a question, but wanted to maybe hear you elaborate specifically on what has been observed so far during January and February in the new year with the launch. Then as a follow-up, are you expecting any meaningful level of Q1 seasonality? Tyler, as you know, we're not able to comment on Q1, but we can tell you that it is interesting to launch a drug into a completely new indication. We are learning as we go. You know, the Thanksgiving, Christmas was interesting. It was interesting to see some of the summer, you know, camp-related things that happened, people going away to camp. We'll have to see what the cadence is like. I'm going to let Meredith answer the. Yeah. rest of the question. Thanks, Anish, I concur 100% with you that it is interesting to launch. This is the first-ever FDA-approved medicine for the treatment of hyperphagia. We're learning a lot around some of the aspects in the home, or the family, or what will bring them into the office to get seen by the practitioner. Also, I think I've mentioned several times on our last earnings calls that we also are looking at some of the physicians who are increasingly more interested and excited to treat PWS because there actually is a treatment for hyperphagia now. They're opening up clinical practices or PWS-specific clinics. We're hoping to see some of the availability of clinicians improving as we go forward and really strengthening the care that's being delivered out there. It's exciting. We'll hopefully be able to provide you more details as we go along, but, you know, strong interest out there. I will say that on the seasonality front, Jim, would you like to add something? Sure. Tyler, thank you for the good wishes. Yes, I never like to miss an opportunity on the revenue side of Q1 to point out seasonality that impacts all commercial drugs. It shows up in the gross to net. Tyler, as you're aware, but just to communicate again, what tends to happen with folks on, particularly on commercial plans, is they'll reset their copays. That means that's more out-of-pocket that they would incur, except that we offer Soleno One, and we will effectively reimburse them for those copays, so that increases the discount, if you like, on the gross to net. The other phenomenon that can happen is in the disruption of changing plans. Your employer might change plans, you may choose a different plan. There's an opportunity where may move from what we would call our paid bucket of active patients into the free bucket of active patients. Maybe you'll receive four to six weeks of free drug before you move back to paid. It's a seasonality. It doesn't change the underlying growth in active patients, it's just something that does impact the revenue because it will impact the gross to net discount for Q1. We'll obviously be able to give you better color once we get through Q1, and we'll be able to size it at that stage. Your next question comes from the line of Leland Gershell from Oppenheimer. Please go ahead. Thanks. Good afternoon. Thanks for this update, and Jim, just want to add my sentiments as well. Wish you all the best as you move on. Wanted to ask, you know, at the time of approval, as you were entering the initial launch, I guess this is a question directed at Meredith. You had said, I think, that, you know, you'd identified that there are about 300 physicians who were direct treaters of about 20% of PWS patients, and who also influenced the care of another 20%, and I think there were, you know, about 80% of pediatric endocrinologists who had expressed willingness to prescribe VYKAT XR. Just wondering if you could provide us a picture of the, where that landscape is today with respect to physicians' uptake of VYKAT in their practices? Thank you. Yeah, thank you very much for the question. I appreciate that. The phenomena is still there. As we look at the top 300, we think that's the best way to focus on the market and target where we can have deeper penetration. We are seeing strong uptick among the top 300, and the majority of them have more than one patient, so they're repeat writers, which is very exciting to see. And we're continuing to see that those individuals are influencing the treatment patterns across the country. I've mentioned before that we have peer-to-peer programs, so we're doubling down on that. We also have an expert on demand, where many community physicians can reach out to those top practitioners and get guidance on patient selection and what to look for with regard to setting expectations on efficacy and dosing and monitoring, et cetera. That's been very exciting. As we look at moving forward on focusing in on the caregiver aspect, as I mentioned, we're doubling down on webinars and live events and hoping to see that that will drive caregivers to come in and ask for VYKAT XR. Then just, you know, kind of a higher level question on company's philosophy going forward in terms of the expansion, maybe through business development and the like. You obviously have a continuing and growing stream of cash coming in. It may, you know, cost you some to commercialize elsewhere and also advance your next program, but seems like you'll have firepower to do, you know, beyond that. Just wondering if you could give us any some thoughts as Soleno continues to evolve and develop its footprint. Thank you. Yep. Thanks, Leland. I think the most important thing remains successful commercialization of VYKAT. I think it starts with the U.S., but the next step is outside the U.S., EU, other geographies, et cetera. The next thing is, I'd say, the lower-hanging fruit of using VYKAT itself for other things, which are high likelihood of success situations like GSD I. Those are our primary targets, and we obviously continue to look at things on the outside. I don't expect imminent activity on that front, but we certainly will, in the longer term, look at doing that too. All right, that's helpful. Thanks so much. Your next question comes from the line of Brian Skorney from Baird. Please go ahead. Hey, good afternoon, guys. Thanks for taking the question, and Jim, congrats on the retirement as well. Sorry to see you go. You have six patents listed in the Orange Book for VYKAT XR, with the four longest duration ones going out to 2035. I think when you got approval last year, we talked a little bit, you know, in vagaries about the label creating some opportunity for even longer dated IP. Just wondering if you could give us your current thoughts on exclusivity of VYKAT XR based on where you are across patent prosecution. Just real quick on COGS, just wanted to get guidance if what we're seeing is product that was already expressed through R&D and if there will be sort of a true-up this year in terms of the gross margin. Thanks. Sure. Let me take the first part, Jim can take the second part of it. On the exclusivity front, you're right. When we got approved, we had talked about the possibility of extension of IP beyond where we are today. I think what you saw with the listing of the 2035 patent is a step in that direction. It's a patent that's specific to methods of treating hyperphagia and food-related behaviors. That particular family, the related patents, have the ability to be extended into the late 2030s. We have also stated that we have filed additional IP, although we have not discussed the details of that. Stay tuned on that. Yes, that's the plan on exclusivity. Jim? Brian, to your point, and thanks for your wishes. To your specific point, we still do have a little bit of, if you like, the zero-cost inventory flowing through, so inventory that was in the supply chain prior to approval. Anticipate that COGS will just gently nudge up. They should stay in mid-single digits, though, so they'll just nudge up as we get full cost through the supply chain. Great. Thank you. Your next question comes from the line of James Condulis from Stifel. Please go ahead. Hey, thanks for taking our question. It's Mark on for James. Yeah, I guess as it relates to the EU side of things, I think it's interesting, we've now seen Skyclarys get approval and trofinetide trending in the negative direction with the votes. I guess in the context of that, how are you thinking about, you know, these as potential analogs and EMA's overall comfort with perhaps maybe imperfect clinical data in the rare disease space? Just kind of your overall broader comfort with the EU approval. The second question also on EU is, you know, when do you think you'll kinda have the 180-day questions in hand for the filing? Thank you. Yeah. On the EU approval, you're right. I think it's fair to say that decisions on the rare disease side go in one direction or the other, and you know, we've seen other examples. You know, Translarna is another example, which was approved in Europe for a long time, did not see an approval here. These things are always custom. Rare disease datasets are never perfect. We have to just play out the process and see. We have day 120 questions. We responded to day 120 questions in a timely manner, expecting the day 120 questions by the end of this month, so imminently, and we'll see what they say. I think, as we have said in the past, the nature of the key questions were around the proof of efficacy using randomized withdrawal as the key trial, the fact that the same patients were in the early as well as the late part of the study, and does that create potential for bias, et cetera. Clearly, you know, these are questions that the FDA asked us as well, and we were able to prevail, so we will attempt to do the same here. Hard to predict the outcome, though. In terms of timing of the 180-day, I would say imminently. I think they're supposed to be February 26th. Thanks. The next question comes from the line of Katherine Delloruso from LifeSci Capital. Please go ahead. Hi, congrats on the strong quarter, and congrats, Jim, on the retirement and for taking our questions. Yeah, I guess, just a few more follows on Europe, just given the, it's possibly around the corner. Yeah, just thinking about just the potential launch trajectory in Europe versus U.S., are there anything, you know, key learnings that can be had from the U.S. experience that could accelerate the uptake? I guess if you were to commercialize on your own, any comments on the sales force that you think you would need there? Meredith, would you like to take that? Sure, happy to take that. We're still looking at what the size of the field force would look like. Most specifically, we're focusing in on potentially Germany and Austria, the first to launch, so we're looking at what the marketplace looks like there. U.S. launch experience. Yeah, U.S. launch experience. I think the one other thing that Anish had mentioned in his comments, though, about Europe is one of the phenomena is that there are more centers of excellence and tighter treatment over in Europe, that's a little bit different than here in the U.S. With regard to launch success, obviously, it's making sure that there's strong education of the treaters and making sure that they understand exactly the patient population that they'll be treating, and the selection of that patient population has been really key in the United States. Great, thanks again. Next question comes from the line of Yale Jen from Laidlaw and Company. Please go ahead. Good afternoon, thanks for taking the question. First, Jim, congratulations on your retirement, and hopefully you enjoy the good life going forward. My first question is that given that the drug has a great start for the first year, and do you guys feel that for the next, to getting the next wave of patients, is that more difficult or just a different approach to accomplish that? I have a follow-up. Sure. Meredith, do you want to take that? Yeah, I'm happy to take that. I think what we're pleased to see is that we're getting a spectrum across the patient population. I mentioned that the majority of patients are coming in, ages four to 26, but we're also really pleased that we've reached greater penetration in the younger adults, I'll say, even though up to 45. That population definitely has more comorbidities, if you will, as they get older. We're seeing a broad spectrum, and so we continue to see a broad. We believe we'll see a broad spectrum as we move into 2026. Okay, great. That's very helpful. Maybe just one in the product development or lifecycle management questions, which is that, are you guys also thinking about maybe the next gen, product, follow DCCR? If so, what sort of, attribute you think that may, you want to have? That's a good question, Yale. As you know, this, what we are doing is a once-a-day pill, so there are limits to what you can do with regards to improving upon that. That said, we do have some internal programs on lifecycle management, which I'm not able to discuss today, but we do hope to discuss later this year. Okay, maybe last question here. In terms of DCCR, the mechanism of actions for GSD I, could you elaborate a little bit more? Thanks. Yeah. The, as you know, the critical problem in GSD I is life-threatening hypoglycemia. We know that when you target certain channels in the beta cells of the pancreas, you can suppress the secretion of insulin, which means that you can elevate levels of glucose. The problem that occurs in GSD I is that in order to keep glucose levels higher, these patients are required to take very regular feedings of cornstarch all day, including through the night. What is very desirable is to be able to elevate those blood glucose levels enough that they don't get hypoglycemic. There is actually interesting information and published data using the parent molecule, and we've spoken with KOLs who have tried it. It works, as we know, in situations like CHI as well, the side effect profile is such that it's difficult to tolerate. When we're looking at VYKAT XR, DCCR, and the low stable levels that we will have in the blood, we expect a very different side effect profile and should have the ability to elevate levels of glucose very precisely. Okay, great. Thanks a lot, and again, congrats on the progress. Thanks, Yale. Your next question comes from the line of Derek Archila from Wells Fargo. Please go ahead. Good afternoon. Thanks for taking the questions. Jim, congrats. Wishing you well, and great working with you. Yeah, just two brief ones. I just wanted to clarify. On the seasonality component, you talked about kind of impact of price and kind of free drug rate, but, you know, how much of an impact do you expect in terms of the patient visits and scripts in the first quarter? Meredith? Yeah, I think what we were saying is that we're not really commenting on the first quarter numbers as of right now. With regard to seasonality and the growth to net, I think Jim talked about it. As you know, a lot of patients are coming in. What we didn't see, we launched in March of last year. Now we're going into January, where the copay will re-up for a lot of the commercial payment patients. As Jim mentioned, with Soleno One, we offer copay support for commercial patients, and we pay down to zero on the copay. That's an potential what we'll see in the growth net. Yeah, let me ask this a different way. I guess for typical Prader-Willi patients, do they tend to have, you know, seasonality in terms of their patient visits with their physicians? Derek, I think, again, I'll point you back to the fact that we're launching the first hyperphagia drug in this space, and we're learning as we go. What we know about visits that patients have based on claims data is that the younger patient population, which is a four to 26-year-old age group, has about four to six touch points with healthcare providers over the year. What we know from conversations with KOLs, people who run these top 300 practices or, you know, top 10 practices, is that their practices are pretty crowded, and you schedule your appointments a year out or more. The visits do happen, and there is this particular cadence of visits. Whether it's different in the first quarter or not, we'll find out. Got it. Just to follow up, just wanted to know in terms of inventory and stocking and forecast, if there's any comments there. Thanks. Jim. Yeah, we work with PANTHERx Rare, you know, one specialty pharmacy. You know, they just went through the holiday period. We'll have to sort of be able to do a deep dive to really understand anything, but nothing untoward that we're aware of. Got it. Excellent. Thanks, guys. Thanks, Derek. Your next question comes from the line of Kalpit Patel from Wolfe Research. Please go ahead. Hey, thank you for taking our question. Just on the active patients, number that you gave, the growth in quarter-over-quarter is not keeping pace with the growth in new patient start forms. Is that mainly driven by insurance-related delays, or is that more of a function of the discontinuation rate, or is it a mix of both factors? How should we think about this gap moving forward? I think a very important consideration is the time it takes for benefits assessment. When we get a start form, you don't instantly start someone on drug. They go into a benefits assessment time, which, you know, will take 30-ish days, give or take. We don't think there's any issues with reimbursement that have been encountered that are significant. There will always be a lag between the number of new patient start forms and the number of patients who will be active for that quarter. Meredith, anything to add to that? I think that was a perfect answer. I think that we're looking at a little bit of a mix of all of the above, but we're pleased with, as I mentioned, the ability to convert start forms into patients and reimburse claims. We're gonna continue to do that and double down on that in 2026 and believe that we'll be very successful. Got it. One more on our end. I know you mentioned the long-term discontinuation rate, but do you forecast the discontinuation rate meaningfully fluctuating between now and the end of the year? How might that affect the active patient growth in 2026? Thank you. Good question. I mean, we have to see. I mean, what we have seen so far, I think, is very acceptable for a drug that's treating such a significantly comorbid condition. If we remain in this zone of 15-20, thereabout, I think that's a really good outcome. It's difficult for us to predict if it changes between now and the end of the year. I'm sure it'll go up and down, it'll fluctuate, but I don't see a reason why there would be major changes during the year. Not sure if that answers your question. Yeah, that answers it. Thank you. Congrats, Jim, on the retirement. Thank you. Ladies and gentlemen, as a reminder, if you would like to ask a question, please press star followed by one on your touch-tone phone. If you are using a speakerphone, please make sure to lift your handsets before pressing any case. Your next question comes from the line of Ram Selvaraju from H.C. Wainwright. Please go ahead. Thanks so much for taking our questions. I just wanted to ask about whether you are evaluating other disease indications in which to explore VYKAT XR beyond glycogen storage disease, and if so, what some of these indications might be. If, for example, there's any plan to potentially revisit the utility of the drug in Smith-Magenis syndrome or other conditions of that ilk. Secondly, I just wanted to clarify whether you anticipate any potential pricing flexibility impact if you were to launch the drug yourself in Europe or through a partner, if there might potentially be any spillover to the U.S. pricing paradigm or if ultimately this is a non-factor given the rarity of Prader-Willi syndrome. Lastly, I don't know if you can comment on any underlying dynamics with respect to the discontinuation rate that you're seeing. If it's plateauing, if you are seeing any evidence that it is in fact declining as there is more experience with the drug over time in the PWS population, or if you're seeing the actual percentage rate increase, and if it is increasing by how much? Thank you. Lots of questions, Ram. Okay, I think I got those. The first one is other indications. What we've said in the past, just to remind you, is that there's two categories of rare diseases that we think DCCR could be useful. One is conditions like PWS, where things like hyperphagia and food-related behaviors are a problem. You're right, Smith-Magenis syndrome is one of them, you know, Fragile X, about 10% of Fragile X are the PWS phenotype. Some patients with Angelman have it. There's SIM 1 obesity. There's various other indications where we definitely continue to think that it could be useful, and we are continuing to evaluate it. In terms of the pricing impact of self-launch versus not, I think the challenge right now is that it's a moving target. I think if we had to make a decision today, it would probably say that pricing flexibility is optimal if we control it both here as well as in Europe or outside the country. I'm not sure that it's a non-factor due to the rarity, because even though there has been some conversation about an orphan exclusion in MFN, we haven't seen that actually become reality yet. In terms of the discontinuation rates and are they plateauing? The one phenomenon that we're following very closely is to see if the cadence of discontinuations is going to be like what we saw in the clinical trials. Which is to say that if you stay on drug, you know, through titration and some period of time after, you are very likely to stay on drug. I would say that the early indicators are that that is indeed the case. We think that's very encouraging, but it's something that we're following very carefully and will continue to update you all. Thank you very much. Thank you. We have no further questions at this time. I'm going to turn the call over back to Anish Bhatnagar for closing comments. Sir, please go ahead. Well, thank you all for dialing in today, and we look forward to continuing the conversation with you all. Have a good evening. Ladies and gentlemen, this concludes today's conference call. Thank you very much for your participation. You may now disconnect.